title: Transplantation in chronic lymphocytic leukemia: does it still matter in the era of novel targeted therapies?
abstract: Allogeneic stem cell transplantation (HSCT) offers the only potentially curative approach in chronic lymphocytic leukemia (CLL). However, this applies only to a minority of patients, and is associated with significant treatment-related mortality and morbidity. HSCT must therefore always be considered in view of other, potentially less toxic therapies. Several new agents demonstrate impressive and durable responses in high-risk patients who might be candidates for HSCT. Therefore the choice of HSCT versus a novel agent is one that must be gauged on a patient-by-patient basis; this will change as data mature on the use of these novel agents in CLL.
authors.affiliation: Centre for Haemato-Oncology, Barts Cancer Institute, Queen Mary University of London, Charterhouse Square, London EC1M6BQ, UK; Division of Molecular Genetics, German Cancer Research Center (DKFZ), Im Neuenheimer Feld 580, Heidelberg 69120, Germany.
authors.forename: Fabienne
authors.initials: F
authors.lastname: McClanahan
authors.affiliation: Centre for Haemato-Oncology, Barts Cancer Institute, Queen Mary University of London, Charterhouse Square, London EC1M6BQ, UK. Electronic address: j.gribben@qmul.ac.uk.
authors.forename: John
authors.initials: J
authors.lastname: Gribben
mesh_terms: D018380:Hematopoietic Stem Cell Transplantation / Q000379:methods*; D006801:Humans; D015451:Leukemia, Lymphocytic, Chronic, B-Cell / Q000628:therapy*; D058990:Molecular Targeted Therapy / Q000379:methods*; D012307:Risk Factors; D016019:Survival Analysis; D014184:Transplantation, Homologous; D016896:Treatment Outcome
keywords: Allogeneic hematopoietic stem cell transplantation; Chronic lymphocytic leukemia; GvHD; GvL; High-risk patients; Novel substances